In ENRICH trial [32], comparing Ibrutinb‐R with R‐chemotherapy, both with rituximab maintenance in patients ≥ 60 years with untreated MCL, no significant PFS benefit was observed in TP53 mutated and blastoid patients. Here, TP53 is linked to mantle cell lymphoma.